Global Information
회사소개 | 문의 | 위시리스트

원내 폐렴(HAP) : 파이프라인 리뷰

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2019

리서치사 Global Markets Direct
발행일 2019년 02월 상품 코드 271831
페이지 정보 영문 161 Pages
가격
US $ 2,000 ₩ 2,429,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,858,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,287,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


원내 폐렴(HAP) : 파이프라인 리뷰 Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2019
발행일 : 2019년 02월 페이지 정보 : 영문 161 Pages

원내 폐렴(HAP)은 입원중에 감염된 폐렴으로 정의되고 있습니다. 주요 증상으로서 기침이나 발열, 몸 떨림을 동반한 오한, 의식 혼탁, 두통, 식욕 부진 등을 들 수 있습니다. 주요 위험인자에는 만성 폐질환, 흡연, 치매, 뇌졸중, 뇌 외상, 심장병, 간경변, 당뇨병 등이 있습니다. 주요 치료법은 항생물질이나 생활습관 개선 등입니다.

세계 각국의 원내 폐렴(HAP : Hospital Acquired Pneumonia) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시 최신 동향, 각 임상 단계별 제품 목록, 주요 기업 개요, 주요 치료제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

목차

서론

  • 분석 범위

원내 폐렴(HAP) 개요

치료제 개발

  • 원내 폐렴용 파이프라인 제품 : 개요
  • 원내 폐렴용 파이프라인 제품 : 비교 분석

각 기업에서 개발중인 원내 폐렴 치료제

각 대학/연구기관에서 개발중인 원내 폐렴 치료제

파이프라인 제품 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품
  • 개발 단계가 불명인 제품

원내 폐렴 치료제 : 개발중인 제품 목록(기업별)

원내 폐렴 치료제 : 개발중인 제품 목록(대학/연구기관별)

원내 폐렴 치료제 개발에 참여하고 있는 기업

  • Achaogen Inc.
  • Adenium Biotech ApS
  • Aridis Pharmaceuticals LLC
  • AstraZeneca Plc
  • Cardeas Pharma Corp.
  • Dong-A Socio Group
  • MedImmune, LLC
  • Meiji Seika Pharma Co., Ltd.
  • Melinta Therapeutics, Inc
  • Merck & Co., Inc.
  • Motif Bio Plc
  • Nabriva Therapeutics AG
  • Savara Inc.
  • Serendex Pharmaceuticals A/S
  • Tetraphase Pharmaceuticals Inc.

원내 폐렴 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 병용 제품(Combination Products)별
  • 표적별
  • 작용기서별
  • 투여 방법별
  • 분자 종류별

치료제 개요

  • (amikacin + fosfomycin)
    • 제품 개요
    • 작용기서
    • 연구개발(R&D) 진전 상황
  • (ceftazidime + avibactam sodium)
  • (ceftolozane sulfate + tazobactam sodium)
  • AA-139
  • arbekacin
  • delafloxacin
  • eravacycline
  • iclaprim mesylate
  • lefamulin
  • MEDI-3902
  • MEDI-4893
  • molgramostim
  • Nu-2
  • Panaecin
  • plazomicin sulfate
  • pseudomonas + VAP vaccine
  • Pseudomonas aeruginosa vaccine
  • Qn-2251
  • relebactam
  • tedizolid phosphate
  • tosatoxumab
  • vancomycin hydrochloride

원내 폐렴 치료제 : 파이프라인 제품의 최신 동향

원내 폐렴 치료제 : 개발이 휴지 상태인 제품

원내 폐렴 치료제 : 개발이 중지된 제품

원내 폐렴 관련 제품 개발 마일스톤

  • 주목해야 할 최신 동향 및 프레스 릴리스

부록

도표

KSM 15.10.14

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Companies, H1 2019 (Contd..2), H1 2019
  • Products under Development by Companies, H1 2019 (Contd..3), H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals Inc, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Centauri Therapeutics Ltd, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Cumberland Pharmaceuticals Inc, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by CytaCoat AB, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Plc, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Evaxion Biotech ApS, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune LLC, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co Inc, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics Plc, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Polyphor AG, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co Ltd, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Spero Therapeutics Inc, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Dormant Projects, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Dormant Projects, H1 2019 (Contd..1), H1 2019
  • Hospital Acquired Pneumonia (HAP) - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2019, provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape.

Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 5, 10, 10, 2 and 1 respectively.

Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Hospital Acquired Pneumonia (HAP) - Overview
  • Hospital Acquired Pneumonia (HAP) - Therapeutics Development
  • Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment
  • Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development
  • Hospital Acquired Pneumonia (HAP) - Drug Profiles
  • Hospital Acquired Pneumonia (HAP) - Dormant Projects
  • Hospital Acquired Pneumonia (HAP) - Discontinued Products
  • Hospital Acquired Pneumonia (HAP) - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q